Paraskevas KI, Veith FJ. Transcervical access, reversal of flow and mesh-covered stents: New options in the armamentarium of carotid artery stenting. World J Cardiol 2017; 9(5): 416-421 [PMID: 28603588 DOI: 10.4330/wjc.v9.i5.416]
Corresponding Author of This Article
Kosmas I Paraskevas, MD, PhD, Northern Vascular Centre, Freeman Hospital, Freeman Road, Newcastle-upon-Tyne NE7 7DN, United Kingdom. paraskevask@hotmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. May 26, 2017; 9(5): 416-421 Published online May 26, 2017. doi: 10.4330/wjc.v9.i5.416
Transcervical access, reversal of flow and mesh-covered stents: New options in the armamentarium of carotid artery stenting
Kosmas I Paraskevas, Frank J Veith
Kosmas I Paraskevas, Northern Vascular Centre, Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, United Kingdom
Frank J Veith, Divisions of Vascular Surgery, New York University Langone Medical Center, New York, NY 10016, United States
Frank J Veith, the Cleveland Clinic, Cleveland, OH 44195, United States
Author contributions: Paraskevas KI came up with the idea/topic of the manuscript, searched the literature and wrote the first draft of the manuscript; Veith FJ revised the manuscript and suggested improvements.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Kosmas I Paraskevas, MD, PhD, Northern Vascular Centre, Freeman Hospital, Freeman Road, Newcastle-upon-Tyne NE7 7DN, United Kingdom. paraskevask@hotmail.com
Telephone: +44-73-76104373
Received: December 14, 2016 Peer-review started: December 16, 2016 First decision: January 20, 2017 Revised: March 10, 2017 Accepted: March 21, 2017 Article in press: March 22, 2017 Published online: May 26, 2017 Processing time: 157 Days and 4.4 Hours
Abstract
In the last 25 years, the very existence of carotid artery stenting (CAS) has been threatened on a number of occasions. The initial disappointing results that even lead to the discontinuation of an early randomized controlled trial have improved considerably with time. Novel devices, advanced stent and equipment technology, alternative types of access and several types of filters/emboli protecting devices have been reported to reduce stroke/death rates during/after CAS and improve CAS outcomes. The present review will provide a description of the various technology advances in the field that aim to reduce stroke and death rates associated with CAS. Transcervical access, reversal of flow and mesh-covered stents are currently the most promising tools in the armamentarium of CAS.
Core tip: Carotid artery stenting (CAS) has improved considerably in the last few years. This comprehensive review provides the various technology advances in the field that aim to reduce stroke and death rates after CAS. These include transcervical access, reversal of flow and mesh-covered stents.
